Form 4: United Therapeutics Director Louis W. Sullivan Reports Acquisition of Stock Options and Restricted Stock Units

Director Louis W. Sullivan reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Summary

• On July 25, 2024, Louis W. Sullivan, a director of United Therapeutics Corporation, acquired 1,440 stock options at a price of $336.37 and 590 restricted stock units (RSUs) as part of an annual non-employee director award.
• The stock options vest on July 25, 2025, and expire on July 25, 2034.
• The RSUs also vest on July 25, 2025, and each RSU represents the right to receive one share of United Therapeutics Corporation common stock.
• Following these transactions, Sullivan directly owns 1,440 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and restricted stock units granted to a director. It doesn't inherently indicate positive or negative sentiment, but rather a standard compensation practice.

Positives

• The acquisition of stock options and restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates that a director is incentivized to improve the company's performance.

Key Dates